ResearcherTennessee OncologyActive in the last 2 years

Melissa Lynne Johnson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-9874-1314; OpenAlex author ID A5049294543. Sources: ClinicalTrials.gov.

Their work

Papers: 1
Trials: 1
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2021: 1 trial · 2022: none · 2023: none · 2024: 1 paper

Papers 1

Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Me… Co-author DOI 10.3390/cancers16071323 ↗

Trials 1

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors Study chair NCT04657068 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Kim A Reiss Binder · 1 shared trial, 2021 · strength 0.29
- Trial A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 ↗
Antonio Gonzalez · 1 shared trial, 2021 · strength 0.29
- Trial A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 ↗
Susanna Ulahannan · 1 shared trial, 2021 · strength 0.29
- Trial A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors NCT04657068 ↗
Zev A. Wainberg · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Faithlore Patrice Gardner · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Uwe Pelzer · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Christos K Fountzilas · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Nathan Bahary · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Erkut Hasan Borazanci · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Ignacio Garrido‐Laguna · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗
Teresa Mercade Macarulla · 1 shared paper, 2024 · strength 0.20
- Paper Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab… DOI 10.3390/cancers16071323 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.